These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series. de Waure C; Miglietta A; Nedovic D; Mereu G; Ricciardi W Hum Vaccin Immunother; 2016; 12(2):467-73. PubMed ID: 26308192 [TBL] [Abstract][Full Text] [Related]
43. Challenges for development of meningococcal vaccines in infants and children. Deasy A; Read RC Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801 [TBL] [Abstract][Full Text] [Related]
45. Development of new vaccines against meningococcal disease. Bröker M Arzneimittelforschung; 2003; 53(12):805-13. PubMed ID: 14732960 [TBL] [Abstract][Full Text] [Related]
46. [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations]. Gendrel D Arch Pediatr; 2012 Sep; 19 Suppl 2():S70-6. PubMed ID: 22883370 [TBL] [Abstract][Full Text] [Related]
52. Combined effect of PCV10 and meningococcal C conjugate vaccination on meningitis mortality among children under five years of age in Brazil. Bierrenbach AL; Minamisava R; Alencar AP; Alencar GP; Andrade AL Hum Vaccin Immunother; 2018 May; 14(5):1138-1145. PubMed ID: 29068749 [TBL] [Abstract][Full Text] [Related]
53. Global epidemiology of meningococcal disease and vaccine efficacy. Pollard AJ Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S274-9. PubMed ID: 15597069 [TBL] [Abstract][Full Text] [Related]
54. Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil. Tauil Mde C; Carvalho CS; Vieira AC; Waldman EA Braz J Infect Dis; 2014; 18(4):379-86. PubMed ID: 24698710 [TBL] [Abstract][Full Text] [Related]
55. Critical analysis of old and new vaccines against N. meningitidis serogroup C, considering the meningococcal disease epidemiology in Brazil. Bricks LF Rev Hosp Clin Fac Med Sao Paulo; 2003; 58(4):231-40. PubMed ID: 14534678 [TBL] [Abstract][Full Text] [Related]
56. Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt. Tartof S; Cohn A; Tarbangdo F; Djingarey MH; Messonnier N; Clark TA; Kambou JL; Novak R; Diomandé FV; Medah I; Jackson ML PLoS One; 2013; 8(5):e63605. PubMed ID: 23671685 [TBL] [Abstract][Full Text] [Related]
57. The impact of aggregating serogroups in dynamic models of Neisseria meningitidis transmission. Poore KD; Bauch CT BMC Infect Dis; 2015 Jul; 15():300. PubMed ID: 26223223 [TBL] [Abstract][Full Text] [Related]
58. Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases. Bricks LF; Berezin E J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S67-74. PubMed ID: 16721440 [TBL] [Abstract][Full Text] [Related]
59. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396 [TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt. Kuznik A; Iliyasu G; Lamorde M; Mahmud M; Musa BM; Nashabaru I; Obaro S; Mohammed I; Habib AG PLoS One; 2017; 12(11):e0188595. PubMed ID: 29190699 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]